Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances

Detalhes bibliográficos
Autor(a) principal: Faria, Maria João
Data de Publicação: 2021
Outros Autores: Lopes, Carla Martins, das Neves, José, Lúcio, Marlene
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10284/10209
Resumo: Since HIV was first identified, and in a relatively short period of time, AIDS has become one of the most devastating infectious diseases of the 21st century. Classical antiretroviral therapies were a major step forward in disease treatment options, significantly improving the survival rates of HIV-infected individuals. Even though these therapies have greatly improved HIV clinical outcomes, antiretrovirals (ARV) feature biopharmaceutic and pharmacokinetic problems such as poor aqueous solubility, short half-life, and poor penetration into HIV reservoir sites, which contribute to the suboptimal efficacy of these regimens. To overcome some of these issues, novel nanotechnology-based strategies for ARV delivery towards HIV viral reservoirs have been proposed. The current review is focused on the benefits of using lipid-based nanocarriers for tuning the physicochemical properties of ARV to overcome biological barriers upon administration. Furthermore, a correlation between these properties and the potential therapeutic outcomes has been established. Biotechnological advancements using lipid nanocarriers for RNA interference (RNAi) delivery for the treatment of HIV infections were also discussed.
id RCAP_6dcc238877012dd645497a5982ccabe8
oai_identifier_str oai:bdigital.ufp.pt:10284/10209
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advancesARV deliveryBiotechnology in ARVBiological barriersLipid emulsionsLipid nanoparticlesLiposomesRNAi and ARV codeliverySince HIV was first identified, and in a relatively short period of time, AIDS has become one of the most devastating infectious diseases of the 21st century. Classical antiretroviral therapies were a major step forward in disease treatment options, significantly improving the survival rates of HIV-infected individuals. Even though these therapies have greatly improved HIV clinical outcomes, antiretrovirals (ARV) feature biopharmaceutic and pharmacokinetic problems such as poor aqueous solubility, short half-life, and poor penetration into HIV reservoir sites, which contribute to the suboptimal efficacy of these regimens. To overcome some of these issues, novel nanotechnology-based strategies for ARV delivery towards HIV viral reservoirs have been proposed. The current review is focused on the benefits of using lipid-based nanocarriers for tuning the physicochemical properties of ARV to overcome biological barriers upon administration. Furthermore, a correlation between these properties and the potential therapeutic outcomes has been established. Biotechnological advancements using lipid nanocarriers for RNA interference (RNAi) delivery for the treatment of HIV infections were also discussed.MDPIRepositório Institucional da Universidade Fernando PessoaFaria, Maria JoãoLopes, Carla Martinsdas Neves, JoséLúcio, Marlene2021-09-15T09:08:54Z2021-08-19T00:00:00Z2021-08-19T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10284/10209engFaria, M.J.; Lopes, C.M.; das Neves, J.; Lúcio, M. Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances. Pharmaceutics 2021, 13, 1294. https://doi.org/10.3390/ pharmaceutics130812941999-492310.3390/pharmaceutics13081294info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-06T02:09:27Zoai:bdigital.ufp.pt:10284/10209Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:46:56.089848Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances
title Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances
spellingShingle Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances
Faria, Maria João
ARV delivery
Biotechnology in ARV
Biological barriers
Lipid emulsions
Lipid nanoparticles
Liposomes
RNAi and ARV codelivery
title_short Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances
title_full Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances
title_fullStr Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances
title_full_unstemmed Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances
title_sort Lipid nanocarriers for anti-HIV therapeutics: a focus on physicochemical properties and biotechnological advances
author Faria, Maria João
author_facet Faria, Maria João
Lopes, Carla Martins
das Neves, José
Lúcio, Marlene
author_role author
author2 Lopes, Carla Martins
das Neves, José
Lúcio, Marlene
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório Institucional da Universidade Fernando Pessoa
dc.contributor.author.fl_str_mv Faria, Maria João
Lopes, Carla Martins
das Neves, José
Lúcio, Marlene
dc.subject.por.fl_str_mv ARV delivery
Biotechnology in ARV
Biological barriers
Lipid emulsions
Lipid nanoparticles
Liposomes
RNAi and ARV codelivery
topic ARV delivery
Biotechnology in ARV
Biological barriers
Lipid emulsions
Lipid nanoparticles
Liposomes
RNAi and ARV codelivery
description Since HIV was first identified, and in a relatively short period of time, AIDS has become one of the most devastating infectious diseases of the 21st century. Classical antiretroviral therapies were a major step forward in disease treatment options, significantly improving the survival rates of HIV-infected individuals. Even though these therapies have greatly improved HIV clinical outcomes, antiretrovirals (ARV) feature biopharmaceutic and pharmacokinetic problems such as poor aqueous solubility, short half-life, and poor penetration into HIV reservoir sites, which contribute to the suboptimal efficacy of these regimens. To overcome some of these issues, novel nanotechnology-based strategies for ARV delivery towards HIV viral reservoirs have been proposed. The current review is focused on the benefits of using lipid-based nanocarriers for tuning the physicochemical properties of ARV to overcome biological barriers upon administration. Furthermore, a correlation between these properties and the potential therapeutic outcomes has been established. Biotechnological advancements using lipid nanocarriers for RNA interference (RNAi) delivery for the treatment of HIV infections were also discussed.
publishDate 2021
dc.date.none.fl_str_mv 2021-09-15T09:08:54Z
2021-08-19T00:00:00Z
2021-08-19T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10284/10209
url http://hdl.handle.net/10284/10209
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Faria, M.J.; Lopes, C.M.; das Neves, J.; Lúcio, M. Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances. Pharmaceutics 2021, 13, 1294. https://doi.org/10.3390/ pharmaceutics13081294
1999-4923
10.3390/pharmaceutics13081294
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130336065486848

Registros relacionados